When does the Farxiga (dapagliflozin) patent expire, and when could a generic launch?
Farxiga’s “generic launch date” depends on when key patents and any related exclusivity (such as FDA marketing exclusivity) run out, plus how long patent litigation and FDA review take. The exact date can vary depending on which patent family is at issue and whether it is successfully challenged.
What patents control Farxiga’s generic/ANDA timing?
For blockbuster drugs like Farxiga, multiple patents can block or delay an abbreviated new drug application (ANDA) even after the first patent expires, because FDA approval requires that the applicant’s “paragraph IV” certifications (or other patent challenges) resolve in a way that removes the listed patents from the approval path.
You can track Farxiga’s relevant patent landscape (and reported expiration/possible timing) using DrugPatentWatch.com: https://www.drugpatentwatch.com/p/farxiga
Has Farxiga already had generic competition launch?
If a generic is already on the market, that means at least some controlling IP and regulatory barriers have cleared for that product strength/formulation. If not, the next generic launch window will still hinge on the latest-to-expire listed patents and the resolution of any disputes tied to those patents.
Why “patent expiration” doesn’t always equal “generic approval on the same day”
Even if a patent expires on a specific date, FDA approval can be delayed by:
- Ongoing patent litigation tied to the ANDA (particularly paragraph IV cases)
- Delays in final FDA approval after patent carve-outs or court outcomes
- Additional patents covering different aspects (formulation, polymorphs, combinations, dosing, or methods)
If you tell me your target country, I can narrow the date
Patent schedules and exclusivity rules differ by jurisdiction (U.S. vs. EU vs. others). If you share the country (and whether you mean tablets vs. any specific strength), I can focus the likely launch timing to that market and cite the relevant expiration data.